Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
XGN Exagen Inc
- Stocks
- Healthcare
- NASDAQ: XGN
Price (delayed)
$6.95
Market cap
$125.12M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.84
Enterprise value
$137.36M
Exagen is dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. Exagen has developed and
Highlights
The EPS has grown by 23% YoY
The company's gross profit rose by 2.7% YoY
The company's net income rose by 20% YoY but it fell by 2.6% QoQ
Exagen's equity has plunged by 68% YoY and by 33% from the previous quarter
XGN's quick ratio has dropped by 57% year-on-year and by 16% since the previous quarter
Key stats
What are the main financial stats of XGN
Market
Valuations
Earnings
Shares outstanding
18M
Market cap
$125.12M
Enterprise value
$137.36M
Price to earnings (P/E)
N/A
Price to book (P/B)
19.43
Price to sales (P/S)
2.27
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.42
Revenue
$56.72M
Gross profit
$33.64M
Operating income
-$14M
Net income
-$15.51M
EBIT
-$13.27M
EBITDA
-$10.66M
Free cash flow
-$15.45M
Per share
Balance sheet
Liquidity
EPS
-$0.84
EPS diluted
-$0.84
Free cash flow per share
-$0.83
Book value per share
$0.36
Revenue per share
$3.06
TBVPS
$2.17
Total assets
$40.29M
Total liabilities
$33.89M
Debt
$23.44M
Equity
$6.4M
Working capital
$18.51M
Debt to equity
3.66
Current ratio
2.32
Quick ratio
1.85
Net debt/EBITDA
-1.15
Margins
Efficiency
Dividend
EBITDA margin
-18.8%
Gross margin
59.3%
Net margin
-27.3%
Operating margin
-24.7%
Return on assets
-34.9%
Return on equity
-133.7%
Return on invested capital
-36.4%
Return on capital employed
-50.4%
Return on sales
-23.4%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
XGN stock price
How has the Exagen stock price performed over time
Intraday
-0.43%
1 week
5.3%
1 month
11.56%
1 year
261.98%
YTD
69.51%
QTD
93.59%
Financial performance
How have Exagen's revenue and profit performed over time
Revenue
$56.72M
Gross profit
$33.64M
Operating income
-$14M
Net income
-$15.51M
Gross margin
59.3%
Net margin
-27.3%
The operating margin has grown by 24% YoY
The operating income rose by 23% year-on-year but it has declined by 2.7% since the previous quarter
XGN's net margin is up by 21% year-on-year
The company's net income rose by 20% YoY but it fell by 2.6% QoQ
Price vs fundamentals
How does XGN's price correlate with its fundamentals
Growth
What is Exagen's growth rate over time
Valuation
What is Exagen stock price valuation
P/E
N/A
P/B
19.43
P/S
2.27
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.42
The EPS has grown by 23% YoY
Exagen's equity has plunged by 68% YoY and by 33% from the previous quarter
The P/S is 127% more than the last 4 quarters average of 1.0
Efficiency
How efficient is Exagen business performance
The company's return on equity has shrunk by 76% YoY and by 33% QoQ
The ROS has grown by 24% YoY
The company's return on invested capital rose by 12% YoY but it fell by 2.5% QoQ
Exagen's return on assets has decreased by 9% QoQ and by 4.8% YoY
Dividends
What is XGN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for XGN.
Financial health
How did Exagen financials performed over time
The total assets is 19% greater than the total liabilities
XGN's quick ratio has dropped by 57% year-on-year and by 16% since the previous quarter
Exagen's current ratio has plunged by 52% YoY and by 14% from the previous quarter
Exagen's equity has plunged by 68% YoY and by 33% from the previous quarter
The debt to equity has soared by 52% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.